LON:STX Shield Therapeutics (STX) Share Price, News & Analysis GBX 6.15 +0.25 (+4.24%) As of 12:18 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesBuy This Stock About Shield Therapeutics Stock (LON:STX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Shield Therapeutics alerts:Sign Up Key Stats Today's Range 5.90▼ 6.1550-Day Range 5.86▼ 9.5052-Week Range 2.25▼ 12.50Volume1.40 million shsAverage Volume2.25 million shsMarket Capitalization£65.71 millionP/E RatioN/ADividend YieldN/APrice TargetGBX 15Consensus RatingBuy Company Overview Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched Accrufer® in the U.S. with an exclusive, multi-year commercial agreement with Viatris Inc. (Viatris). Outside of the U.S., the Company has licensed the rights to four specialty pharmaceutical companies. Feraccru® is commercialized in the UK and European Union by Norgine B.V. (Norgine), which also has marketing rights in Australia and New Zealand. Shield also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialization of Accrufer®/ Feraccru® in China, Hong Kong, Macau and Taiwan; with Korea Pharma Co., Ltd. for the Republic of Korea (Korea Pharma); and with KYE Pharmaceuticals Inc. for Canada. Accrufer®/Feraccru® has patent coverage until the mid-2030s. Accrufer®/Feraccru® are registered trademarks of Shield Therapeutics. Read More Shield Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks31st Percentile Overall ScoreSTX MarketRank™: Shield Therapeutics scored higher than 31% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingShield Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and no sell ratings.Upside PotentialShield Therapeutics has a consensus price target of GBX 15, representing about 146.3% upside from its current price of GBX 6.09.Amount of Analyst CoverageShield Therapeutics has received no research coverage in the past 90 days.Read more about Shield Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Shield Therapeutics is -3.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Shield Therapeutics is -3.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioShield Therapeutics has a P/B Ratio of 111.29. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for STX. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldShield Therapeutics does not currently pay a dividend.Dividend GrowthShield Therapeutics does not have a long track record of dividend growth. News and Social Media1.3 / 5News SentimentN/A Search Interest173 people have searched for STX on MarketBeat in the last 30 days. This is an increase of 125% compared to the previous 30 days.MarketBeat Follows1 people have added Shield Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership0.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Shield Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders3.02% of the stock of Shield Therapeutics is held by insiders.Percentage Held by Institutions1.11% of the stock of Shield Therapeutics is held by institutions.Read more about Shield Therapeutics' insider trading history. Receive STX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Shield Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. STX Stock News HeadlinesShield Therapeutics plc (SHIEF) Q1 2026 Sales/Trading Call TranscriptMay 5, 2026 | seekingalpha.comShield Therapeutics Turns Profitable in Q1 as ACCRUFeR Sales Climb and CFO Steps DownMay 1, 2026 | uk.finance.yahoo.comRead now. Do not delete. You’ve been warned.Three Nobel Prize Winners expose this once-in-a-generation wealth shift: “Don’t Say I Didn’t Warn You” Porter Stansberry exposes how the convergence of three immense forces is about to rewrite everything about the American way of life: how you work, save, invest… it’s all about to change.May 28 at 1:00 AM | Porter & Company (Ad)Shield Therapeutics drops as CFO exits and Medicaid concerns weighMay 1, 2026 | finance.yahoo.comShield Therapeutics Begins Japanese Phase II Trial of ACCRUFeR in PAHApril 28, 2026 | uk.finance.yahoo.comShield Therapeutics Gains Pediatric Boost as Ferric Maltol Data Published in Leading JournalApril 2, 2026 | theglobeandmail.comShield Therapeutics Updates Voting Rights as Iron Drug Expansion ContinuesFebruary 27, 2026 | tipranks.comShield Therapeutics Iron Deficiency Drug Approved for ChildrenFebruary 18, 2026 | marketwatch.comSee More Headlines STX Stock Analysis - Frequently Asked Questions How have STX shares performed this year? Shield Therapeutics' stock was trading at GBX 10 at the start of the year. Since then, STX shares have decreased by 39.1% and is now trading at GBX 6.09. How were Shield Therapeutics' earnings last quarter? Shield Therapeutics plc (LON:STX) announced its quarterly earnings data on Thursday, April, 24th. The company reported ($3.00) EPS for the quarter. Shield Therapeutics had a positive trailing twelve-month return on equity of 103.62% and a negative net margin of 34.53%. How do I buy shares of Shield Therapeutics? Shares of STX stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of Shield Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Shield Therapeutics investors own include Rockwell Medical (RMTI), AstraZeneca (AZN), Cellectis (CLLS). Company Calendar Last Earnings4/24/2025Today5/28/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryComputer Hardware Current SymbolLON:STX CIKN/A Webwww.shieldtherapeutics.com Phone+44-191-5118500FaxN/AEmployees40,000Year FoundedN/APrice Target and Rating Average Price Target for Shield TherapeuticsGBX 15 High Price TargetGBX 15 Low Price TargetGBX 15 Potential Upside/Downside+143.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Trailing Twelve Months)GBX (2) Trailing P/E RatioN/A Forward P/E Ratio86.91 P/E GrowthN/ANet Income-£36.28 million Net Margins-34.53% Pretax MarginN/A Return on Equity103.62% Return on Assets-47.85% Debt Debt-to-Equity Ratio-199.87 Current Ratio0.90 Quick Ratio2.16 Sales & Book Value Annual Sales£49.70 million Price / Sales1.32 Cash FlowGBX 0.97 per share Price / Cash Flow6.36 Book ValueGBX 0.05 per share Price / Book112.38Miscellaneous Outstanding Shares1,068,418,000Free FloatN/AMarket Cap£65.71 million OptionableNot Optionable Beta1.88 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free Report This page (LON:STX) was last updated on 5/28/2026 by MarketBeat.com Staff. From Our PartnersBNZI Breakout Watch: AI Growth Meets Turnaround Setup!Banzai International (NASDAQ: BNZI) reported full-year 2025 revenue of $12.2 million, up 169% year-over-year, ...Huge Alerts | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredThe math on the SpaceX IPO is brokenSpaceX is expected to go public at a $1.75 trillion valuation. For investors to see a 10x return, the company ...Weiss Ratings | SponsoredA 25,000% opportunityAngel investor Jason Calacanis - who made a fortune on an early Uber stake - says Elon Musk's latest project c...The Oxford Club | SponsoredI paid $5,000 to hear Elon say thisOne investor paid $5,000 to be in a private room with Elon Musk in Los Angeles - and what he heard confirmed a...InvestorPlace | SponsoredThis Tech Could Be Bigger Than Apple, Amazon, and Microsoft CombinedA breakthrough technology backed by Elon Musk, Sam Altman, and Nvidia CEO Jensen Huang may hold the answer to ...Altimetry | SponsoredThe AI Shakeout Is Coming — Most Investors Won’t SurviveEvery major tech shift follows the same pattern: hype, a brutal shakeout, then a handful of winners that take ...Prosperity Research | SponsoredSMX Could Be One of the Most Interesting Small Caps Right NowSMX (Security Matters) Public Limited is developing molecular-level markers embedded into plastics, fuels, met...Smallcaps Daily | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Shield Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Shield Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
